Mark Matijevic
About
Mark Matijevic is a scholar working on Immunology, Molecular Biology and Oncology.
According to data from OpenAlex, Mark Matijevic has authored 20 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Mark Matijevic's work include PARP inhibition in cancer therapy (4 papers), Immunotherapy and Immune Responses (3 papers) and Thyroid Cancer Diagnosis and Treatment (3 papers). Mark Matijevic is often cited by papers focused on PARP inhibition in cancer therapy (4 papers), Immunotherapy and Immune Responses (3 papers) and Thyroid Cancer Diagnosis and Treatment (3 papers). Mark Matijevic collaborates with scholars based in United States, Japan and United Kingdom. Mark Matijevic's co-authors include Robert G. Urban, Mary Lynne Hedley, Jennifer Wilson, Teresa M. Darragh, Naomi Jay, Michael J. Berry, Janet L. Lathey, Joel M. Palefsky, Vivian Weinberg and Barbara Klencke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Mark Matijevic
18 papers receiving 440 citations
Peers
Mark Matijevic
Minggao Guo China
Jennifer A. Cartwright United Kingdom
Anita Schildknecht Switzerland
Jacqueline Miller United States
Vivian Lim United States
Joern-Peter Halle Germany
Dianyuan Zhao China
Laura Marín Spain
L A Falk United States
Penghui Jia China
Citations per year, relative to Mark Matijevic Mark Matijevic (= 1×)
peers
Minggao Guo
Countries citing papers authored by Mark Matijevic
Since
Specialization
Citations
This map shows the geographic impact of Mark Matijevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Matijevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Matijevic more than expected).
Fields of papers citing papers by Mark Matijevic
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark Matijevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Matijevic. The network helps show where Mark Matijevic may publish in the future.
Co-authorship network of co-authors of Mark Matijevic
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Matijevic. A scholar is included among the top collaborators of Mark Matijevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Matijevic. Mark Matijevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Xiaodong, et al.. (2025). Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis. Clinical Pharmacology in Drug Development. 14(9). 656–668.
2.
Wang, Xiaodong, Richard Kirk, Mark Matijevic, et al.. (2024). Pharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers. Advances in Therapy. 42(2). 813–829.
3.
Bao, Weili, Shan Su, Yunfeng Liu, et al.. (2024). Effect of Obexelimab Surrogate Monoclonal Antibody on Inhibition of Autoimmune Hemolytic Anemia (AIHA) Induction in Mice. Blood. 144(Supplement 1). 3834–3834.
4.
Merrill, Joan T., Joel M. Guthridge, Miles Smith, et al.. (2023). Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind , Randomized, Placebo‐Controlled , Phase 2 Trial. Arthritis & Rheumatology. 75(12). 2185–2194.
5.
Plummer, Ruth, Nicola Cresti, Yvette Drew, et al.. (2020). First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. British Journal of Cancer. 123(4). 525–533.
6.
Nakai, Kenya, Sanae Yasuda, Mark Matijevic, et al.. (2018). Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist. Proceedings for Annual Meeting of The Japanese Pharmacological Society. WCP2018(0). PO1–11.
7.
Tahara, Makoto, Martin Schlumberger, Rossella Elisei, et al.. (2017). Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. European Journal of Cancer. 75. 213–221.
8.
McGonigle, Sharon, Jiayi Wu, Donna Kolber‐Simonds, et al.. (2015). Abstract P5-06-03: Combination of the PARP inhibitor E7449 with eribulin +/- carboplatin in preclinical models of triple negative breast cancer. Cancer Research. 75(9_Supplement). P5–6.
9.
Tahara, Makoto, Martin Schlumberger, Rossella Elisei, et al.. (2015). Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology. 33(15_suppl). 6014–6014.
10.
Matijevic, Mark, Hideki Watanabe, Yoshiaki Sato, et al.. (2015). P4‐163: A single dose of the beta‐secretase inhibitor, e2609, decreases CSF bace1 enzymatic activity in cynomolgus monkeys. Alzheimer s & Dementia. 11(7S_Part_18).
11.
Plummer, Ruth, Nicola Cresti, Aneta Suder, et al.. (2014). Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.. Journal of Clinical Oncology. 32(15_suppl). e19531–e19531.
12.
Vergote, Ignace, Douglas W. Ball, Masatoshi Kudo, et al.. (2014). Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.. Journal of Clinical Oncology. 32(15_suppl). 11061–11061.
13.
Bernier, François P., Yoshiaki Sato, Mark Matijevic, et al.. (2013). P4–411: Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimer s & Dementia. 9(4S_Part_22).
14.
Ball, Douglas W., Steven I. Sherman, Barbara Jarząb, et al.. (2012). Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response.. Journal of Clinical Oncology. 30(15_suppl). 5518–5518.
15.
Albala, Bruce, June Kaplow, Robert Lai, et al.. (2012). S4‐04‐01: CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609. Alzheimer s & Dementia. 8(4S_Part_20).
16.
Daniele, Gennaro, Malcolm Ranson, Montserrat Blanco-Codesido, et al.. (2012). Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3030–3030.
17.
Matijevic, Mark, et al.. (2011). Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. Cellular Immunology. 270(1). 62–69.
18.
Mita, Alain C., Monica Mita, John Sarantopoulos, et al.. (2011). Abstract B185: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B185–B185.
19.
Matijevic, Mark & Robert G. Urban. (2005). Use of Interferon-γ ELISPOT in Monitoring Immune Responses in Humans. Humana Press eBooks. 302. 237–252.
20.
Klencke, Barbara, Mark Matijevic, Robert G. Urban, et al.. (2002). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.. PubMed. 8(5). 1028–37.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Minggao Guo Breakdown of academic impact, for papers by Jennifer A. Cartwright Breakdown of academic impact, for papers by Anita Schildknecht Breakdown of academic impact, for papers by Jacqueline Miller Breakdown of academic impact, for papers by Vivian Lim Breakdown of academic impact, for papers by Joern-Peter Halle Breakdown of academic impact, for papers by Dianyuan Zhao Breakdown of academic impact, for papers by Laura Marín Breakdown of academic impact, for papers by L A Falk Breakdown of academic impact, for papers by Penghui Jia